UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

Author: Kielhorn Adrian   Porter Duncan   Diamantopoulos Alexander   Lewis Gavin  

Publisher: Informa Healthcare

ISSN: 1473-4877

Source: Current Medical Research and Opinion, Vol.24, Iss.9, 2008-09, pp. : 2639-2650

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content